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Abstract 
An efficient immunosurveillance of CD8+ 
T cells in the periphery depends on 
positive/negative selection of thymocytes 
and thus on the dynamics of antigen 
degradation and epitope production by 
thymoproteasome and 
immunoproteasome in the thymus. 
Although studies in mouse systems have 
shown how thymoproteasome activity 
differs from that of immunoproteasome 
and strongly impacts on the T cell 
repertoire, the proteolytic dynamics and 
the regulation of human 
thymoproteasome are unknown. By 
combining biochemical and computational 
modeling approaches, we show here that 
human 20S thymoproteasome and 
immunoproteasome differ not only in the 
proteolytic activity of the catalytic sites 
but also in the peptide transport. These 
differences impinge upon the quantity of 
peptide products rather than where the 
substrates are cleaved. The comparison 
of the two human 20S proteasome 
isoforms depicts different processing of 
antigens that are associated to tumors 




The immune system constantly patrols 
the human body to detect pathological 
situations. An important role in this is 
played by CD8+ T cells, which recognize 
and kill infected and aberrant cells. 
Because of their high specificity and 
cytotoxic activity, CD8+ T cells are 
intensely investigated as tools and/or 
targets of immunotherapies against 
infection, autoimmunity and cancer (1-3).  
CD8+ T cells recognize, via their T cell 
receptor (TCR) coupled to a CD8 
molecule, a specific epitope presented in 
the cleft of major histocompatibility 
complex class I (MHC-I) molecules (4). 
The cytotoxic CD8+ T cells are primed in 
lymph nodes. The naïve CD8+ T cells 
arrive in the lymph nodes from the 
thymus. In this latter organ, thymocytes, 
prior to becoming mature naïve CD8+ T 
cells, undergo a series of 
maturation/selection processes called 
central tolerance. According to one of the 
most accepted models, central tolerance 
can be summarized in two selection steps. 
Initially, thymocytes undergo a positive 
selection step, which takes place in the 
thymic cortex, leading to the survival and 
maturation of double-positive thymocytes 
that express TCRs with intermediate 
affinity and/or avidity for MHC-I-peptides 
complexes. Afterwards, in the thymic 
medulla thymocytes undergo the 
negative selection step, which leads to 
the elimination of thymocytes recognizing 
self-peptide-MHC complexes with a high 
affinity (5).  
The large majority of peptides bound to 
MHC-I molecules and recognized by CD8+ 
T lymphocytes are generated by 
proteasome, which is the final effector of 
the ubiquitin-proteasome system (6). 
This barrel shaped protease can break 
proteins and release the peptide 
fragments or re-ligate them, thereby 
forming new (spliced) peptides with 
sequences that do not recapitulate the 
parental protein (4). The proteasome is a 
multi-subunit enzyme, which has a 20S 
proteasome as the core and various 
proteins bound at both side of its gate, 
where they play a regulatory role (4). The 
26S proteasome, comprising of a 20S 
proteasome core coupled to a 19S 
regulatory complex, is often the most 
active form of proteasome, with an 
increasing amount of evidence suggesting 
that the 20S proteasome is independently 
functional and both degrades and 
activates proteins in cells (4,7,8). The 
20S proteasome is constituted of four 
rings, two a rings at the apexes and two 
b rings forming the central chamber. Each 
ring has 7 distinct subunits. Each b ring 
carries three catalytic (i.e., b1, b2, and 
b5) subunits, which have distinct 
preferences for peptide sequence motifs 
(9). Human cells can express different 
isoforms of catalytic subunits, which are 
incorporated in distinct proteasome 
isoforms. Standard proteasome (s-
proteasome) contains b1, b2, and b5 
subunits. Immunoproteasome (i-
proteasome) contains b1i, b2i, and b5i 
subunits and it is present in immune cells 
(constitutively) as well in cells exposed to 
inflammatory milieu. The majority of cells 
express a mixed-type proteasome 
population where both s- and i-
proteasome subunits are present in 
various amount (4). A decade ago, Murata 
and colleagues (10) identified the so-
called thymoproteasome (t-proteasome), 
which carries the b1i, b2i, and b5t 
subunits and has so far only been 
detected in the thymus.  
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To investigate the dynamics and its 
regulation of peptide hydrolysis by the 
20S proteasome and to elucidate 
differences between s- and i-
proteasomes, we previously developed a 
computational mechanistic model of 
proteasome peptide degradation (11) 
(Fig. 1A). The model was constructed 
and compared with many competing 
models in a Bayesian model selection 
framework (12,13) and finally challenged 
with further experimentation. 
Specifically, a series of models was 
constructed with increasing complexity, 
starting from the simplest Michaelis-
Menten model and ignoring the structural 
properties of the proteasome. Kinetic 
time-course data tracking the 
degradation of short fluorogenic peptides 
by 20S proteasomes was used to test 
whether the constructed models were 
able to produce the experimentally 
observed kinetics. Latter data and further 
experimentation were used to yield 
insight into possible dynamics of the 
proteasome and guide the development 
of competing mechanistic models with 
increasing complexity. These models can 
be seen as representing competing 
hypotheses, allowing selection of the 
hypothesis that best justifies our 
experimental data. In contrast to many 
hypothesis testing techniques, Bayesian 
model selection allows us to not only 
reject a likely wrong hypothesis, but also 
rank competing models given 
experimental data (14,15).  
Model development and model selection 
have two aspects to consider: the model 
structure and the model parameters. 
While the model structure can be seen as 
a map, the model parameters essentially 
identify where in that map the dynamics 
of the model can occur. It is therefore of 
interest to define both, model structure 
and model parameters, or in Bayesian 
terms the posterior model distribution 
and the posterior parameter distribution 
(16,17). Our Bayesian model selection 
framework allows us to determine both 
the best model structure and the model 
parameters, each with prior knowledge, 
i.e. the original model distribution (the 
construction of a set of competing models 
and our initial confidence in them) and the 
original parameter distribution (the 
allowed values of a kinetic parameter). 
Both, the suggested model structure and 
the suggested model parameters, will 
contain uncertainty, which can be 
assessed from the posterior distribution 
(18,19). Roughly speaking, the broader a 
posterior parameter distribution is, the 
less information the experimental data 
has contained about this parameter and 
thus the higher the uncertainty. This 
parameter uncertainty will be carried into 
model predictions. To note, in some cases 
not all model parameters must be inferred 
with low uncertainty to make precise 
model predictions (20). This is because 
the systems dynamics may be susceptible 
to alterations in those parameters. 
The applied Bayesian model selection 
framework allowed us to determine the 
best model out of ten constructed 
competing models, however, this does 
not guarantee the accuracy of the winning 
model. A crucial step during model 
development is model validation, 
whereby independent experimental data, 
which were not used for model 
development or model calibration, are 
used to challenge the chosen model. At 
this point it is important to note that any 
model is a simplification of the true 
biochemical system and that in many 
cases a model is developed to explain 
certain aspects of the system, but not all 
(21). Assumptions and simplifications 
often dictate under which conditions the 
system can be described by the 
developed model. For example, in our 20S 
proteasome model we do not include 
proteasome activators such as PA28ab 
and 19S complexes, which may 
significantly alter the observed dynamics 
and its regulation. Model validation can 
help to elucidate the limits and predictive 
potential of the model.  
In most cases the motivation behind 
model development is to generate a 
model to predict system behaviour that 
cannot be observed experimentally. 
However, here we have created a model 
which tests different mechanistic 
hypotheses and derives kinetic 
parameters to in turn characterize 
different proteasome isoforms. As we 
showed that proteasome isoforms differ 
quantitatively but not qualitatively in the 
peptides they generate (22) (at least with 
the sensitivity allowed by the assays 
applied), we can therefore, assume that 
the overall model structure is the same 
for different isoforms and that only the 
kinetic parameters differ. These 
differences can be acquired by comparing 
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the marginal posterior parameter 
distributions in a practical rather than 
statistical manner. That is, differences are 
detected if the distributions to be 
compared overlap only slightly and their 
values with the highest densities clearly 
vary. On the contrary, if the parameter 
distributions to be compared cover the 
same range of possible parameter values 
then either the data does not contain 
sufficient information to detect 
differences, or the parameters indeed do 
not differ.  
In our previous study, parameter 
inference and subsequent comparison of 
posterior distributions of the kinetic 
model parameters (Fig. 1B) showed that 
20S s- and i-proteasome differ in the 
activity of their catalytic sites, in peptide 
transport along their inner channels, and 
in the transport regulation dynamics. 
Because the peptide transport seems to 
often be the rate limiting step of the 
overall peptide-bond hydrolysis (11), 
such differences can impinge upon the 
degradation rate of specific proteins and 
the generation efficiency of specific 
antigenic peptides. Quantitative 
differences in antigenic peptide 
production, after the downstream antigen 
presentation steps, can result in an 
impaired or enhanced CD8+ T cell 
response in vivo (22-25). 
The efficiency of the antigenic peptide 
generation by i-proteasome plays a key 
role in the negative selection of 
thymocytes since medullary professional 
antigen presenting cells (APCs) mainly 
express this proteasome isoform (5). The 
cortical thymic epithelial cells (cTECs), on 
the contrary, mainly express the t-
proteasome, although s-proteasome 
catalytic subunits have also been 
detected (10,26). T-proteasome 
influences the CD8+ T cell repertoire and 
the response to infection in mice (10,27-
29). Some evidence hints towards a 
unique t-proteasome proteolytic activity, 
which, in mice, would lead to the 
generation of t-proteasome-specific 
antigenic peptides with peculiar features 
promoting the positive selection of 
thymocytes (5,28,30). 
As a consequence, the difference between 
the proteolytic dynamics of human i- and 
t-proteasome is supposed to have a large 
impact on the central tolerance, and, 
thus, on the T cell repertoire and on the 
efficacy of CD8+ T cells to recognize 
infected or aberrant cells and eliminate 
them in the human body. 
To study in which aspects of proteolytic 
dynamics the two human proteasome 
isoforms diverge, we have coupled 
biochemical experiments to 
bioinformatics analyses. We have made 
use of the previously developed 
computational model in order to infer the 
kinetic parameters of human 20S t-
proteasomes in comparison to human 20S 
s- and i-proteasomes. We have taken 
advantage of Bayesian inference to obtain 
posterior parameter distributions that 
capture not only the most plausible 
parameter values, but also the 
information and uncertainty carried by 
the experimental data. The latter is of 
particular interest when aiming to detect 
differences between the proteasome 
isoforms. Based on the inferred kinetic 
parameters, we have performed model 
simulations to identify the rate limiting 
steps and peptide transport dynamics of 
human 20S t-proteasome.  
In a second step of the study, we have 
investigated the quantitative differences 
between the three 20S proteasome 
isoforms in substrate cleavage-site 
preferences and epitope production. 
Because of the immunological 
implications that such differences can 
have, we have used synthetic 
polypeptides substrates derived from 
tumors and multiple sclerosis, which are 
two examples of diseases where the MHC-





Human 20S t-proteasome differs 
from s- and i-proteasomes in its 
proteolytic dynamics 
Human b5t subunit has been previously 
detected in different forms of human 
thymoma (31,32), which are tumors 
originating from the epithelial cells of the 
thymus. We have tested whether the t-
proteasome subunit was detectable in 
other cancer-derived cell lines. The mRNA 
of PSMB11, which is the gene encoding 
the human b5t proteasome subunit, is 
also detectable in several tumor-derived 
or immortalized cell lines by RT-PCR (Fig. 
2A); however, its expression does not 
lead to a detectable quantity of b5t 
subunit through the use of a standard 
proteomics strategy (Fig. 2B). This result 
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confirms that in humans the expression of 
the b5t proteasome subunit also seems to 
be limited to the thymus. 
Therefore, not having access to enough 
human cTECs, we generated a cell line, 
C5.5. This cell line is derived from the 
human lymphoblastoid cell line T2. The 
C5.5 cell line expresses mainly the b1i, 
b2i, and b5t subunits, with a b5:b5t 
subunit ratio of 1:2.5, according to our 
quantitative proteomics analysis carried 
out with AQUA peptides (Fig. 2C,D). This 
mixed-type 20S proteasome – here 
referred to as t-proteasome - purified 
from the C5.5 cell line has been compared 
in our study to either the 20S s-
proteasome derived from parental T2 or 
the intermediate-type 20S proteasome 
purified from EBV-immortalized 
lymphoblastoid cell lines (LCLs), which 
has a b5:b5i subunit ratio of 1:2.5 or 
larger (22), and has often been used as 
an example of i-proteasome. 
To investigate the proteolytic dynamics of 
human 20S t-proteasome as compared to 
20S s- and i-proteasomes, we have 
adopted an approach that integrates an 
extensive set of in vitro degradation 
kinetics with computational modeling 
(Fig. 1A-B). We have first purified 20S 
proteasomes from T2, LCL and C5.5 cells 
and used these proteasomes to perform 
in vitro degradation kinetics of the short 
fluorogenic peptides Suc-LLVY-MCA, and 
Z-LLE-MCA, two substrates specific for 
the chymotrypsin-like and caspase-like 
activity of proteasomes. The MCA group 
of these substrates is released upon 
endopeptidase cleavage by proteasomes 
and its fluorescence can be measured 
quantitatively. Murata et al. (10) showed 
that the degradation rate of Suc-LLVY-
MCA - which is mainly carried out by the 
b5/b5i/b5t subunits - diverges between 
mouse i- and t-proteasome. In contrast, 
the cleavage rate of Z-LLE-MCA - which is 
mainly carried out by the b1/b1i subunits 
- should not be different between human 
i- and t-proteasomes, since they carry 
similar amounts of the b1i subunit (Fig. 
2C). Furthermore, although these short 
fluorogenic substrates do not recapitulate 
the full substrate specificity of 
proteasomes (22), they have been 
successfully used to discriminate between 
20S s- and i-proteasome dynamics by the 
development of a computational model 
and its calibration with time course data 
(11) (Fig. 1). We have here applied the 
same computational modeling and model 
calibration approach on Z-LLE-MCA and 
Suc-LLVY-MCA digestion kinetics of 20S 
s-, i- and t-proteasomes. Using Bayesian 
inference techniques, we have obtained 
model fits to the experimental data by 
estimating the model parameters 
resulting in a posterior parameter 
distribution for each 20S proteasome 
isoform (Fig. S1, S2). The posterior 
parameter distribution contains 
information on possible kinetics 
parameter values able to explain the 
experimental datasets and their 
relationship with each other.  
The kinetic differences between 20S s- 
and i-proteasomes confirm our previous 
results (11) and therefore the correct set 
up of our study (Fig. 3A,B). 
Regarding the comparison of the two 
proteasome isoforms mainly involved in 
the positive/negative selection, no 
difference emerges between 20S t- and i-
proteasomes when the estimated 
parameter distributions obtained from Z-
LLE-MCA digestions are compared (Fig. 
S3). On the contrary, in the Suc-LLVY-
MCA degradation kinetics we have found 
differences related to the active-site 
parameters between these two 20S 
proteasome isoforms (Fig. 3A). Most 
apparent is the hydrolysis strength kp (for 
explanations see Table 1), which appears 
to be approximately 4-fold smaller in 20S 
t-proteasome compared to 20S i-
proteasome and therefore recapitulates 
the kp observed in s-proteasome. Also, 
the dissociation constant of the peptide to 
the substrate binding site (KaS), which is 
slightly increased in 20S t-proteasome 
compared to 20S i-proteasome, results 
again in a similar KaS as observed in 20S 
s-proteasome (Fig. 3A). In addition, the 
peptide transport and transport 
regulation parameters differ, indicating 
that the subunit exchange has not only 
local but also global effects on 20S 
proteasome dynamics (Fig. 3B). 
Peptide transport dominates the 
substrate degradation in human t-
proteasome 
By studying inferred posterior parameter 
distribution, we can determine the rate-
limiting steps of the reaction. Previously, 
we showed that for both 20S s- and i-
proteasomes, the gate conformation, 
which determines the peptide transport 
(influx and efflux), is often the rate-
limiting step (11). By in silico simulations 
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we have now found that although several 
kinetics parameters significantly differ 
between 20S i- and t-proteasome, for the 
Suc-LLVY-MCA substrate the rate-limiting 
step of 20S t- and i-proteasomes is the 
peptide transport (Fig. 3C), whereas for 
the Z-LLE-MCA substrate the rate-limiting 
steps are primarily the peptide-bond 
hydrolysis at the active site and 
secondarily the peptide transport (Fig. 
3D).  
Peptide transport also regulates how 
much substrate and product are located 
inside the proteasome chamber over time 
(11). The local substrate concentration 
around the active site Thr1 inside the 
proteasome chamber then strongly 
influences peptide hydrolysis. For a fast 
substrate turnover, the peptide flux 
through the chamber should be large 
enough to allow sufficient supply of new 
substrate molecules and sufficient efflux 
of product molecules. Furthermore, the 
peptide flux should be so that the 
substrate concentration around the active 
site is high enough to obtain reaction 
velocities at a level of vmax, but low 
enough to avoid substrate inhibition (11).  
Taking this into account, differences in 
peptide transport between proteasome 
isoforms, and thus in the filling dynamics 
of the proteasome, should strongly 
influence the observed substrate 
degradation rates. To investigate this 
aspect, we have used the estimated 
posterior parameter distributions for 20S 
i- and t-proteasomes to calculate in silico 
the amount of substrate and products 
inside the proteasome chamber over 
time. In the case of Z-LLE-MCA, our 
simulations show only minor differences 
in the filling kinetics between 20S i- and 
t-proteasomes (Fig. 4A). In contrast, in 
the case of Suc-LLVY-MCA, our 
simulations suggest that the chamber of 
20S t-proteasome is filled more slowly 
with substrate and product molecules 
than the 20S i-proteasome chamber (Fig. 
4B). For both 20S proteasome isoforms, 
our simulations suggest that, in our 
experimental conditions, after 6 h of 
reaction an equal proportion of substrate 
and product molecules are present inside 
the chamber. However, this equal 
proportion is reached faster by 20S i-
proteasome than 20S t-proteasome, 
indicating a stronger peptide bond 
hydrolysis activity by 20S i-proteasome, 
which could be reflected by its higher kp 
value (Fig. 3A). On the contrary, the 
peptide-bond hydrolysis of the Z-LLE-
MCA substrate does not differ between 
these two isoforms and it is much lower 
compared to that of the Suc-LLVY-MCA 
substrate. 
In summary, these analyses highlight 
that the overall substrate degradation 
differences between human 20S i- and t-
proteasome cannot be explained only by 
differences in the active site subunits, but 
they can result from dynamical 
differences that regulate the peptide 
transport efficiencies. 
20S proteasome isoforms 
quantitatively differ in substrate 
cleavage-site strength and the 
generation of self epitopes 
To introduce a further degree of 
complexity in our experimental approach, 
we have analyzed, by mass spectrometry 
(MS), digests obtained after incubation of 
20S proteasomes with eight synthetic 
polypeptides - three derived from the 
melanoma-associated antigen 
gp100PMEL17, and five from myelin sheath 
proteins, which are the main auto-
antigens attacked by CD8+ T cells in 
multiple sclerosis (Table S1). We have 
selected these substrates because of their 
immunogenicity toward CD8+ T cells 
associated with either tumor recognition 
or autoimmune response against 
oligodendrocytes in multiple sclerosis. In 
other words, epitopes derived from these 
antigenic sequences are known to be 
detected at the cell surface by 
autoreactive CD8+ T cells. These 
lymphocytes specifically detect tumor-
associated antigens - e.g. gp100 - and 
multiple sclerosis-associated antigens - 
e.g. myelin oligodendrocyte glycoprotein 
(MOG) and myelin basic protein (MBP) – 
which can be expressed in medullary 
thymic APCs. Nonetheless, they survived 
negative selection in the thymus and are 
present in the periphery as shown in 
various studies (33-37). 
By MS analysis of the peptide products 
generated by 20S s-, i- and t-
proteasomes we have identified 510 non-
spliced and 67 spliced peptide products. 
All spliced and non-spliced peptide 
products are quantifiable in the 
digestions. All 20S proteasome isoforms 
cleave the substrates between the same 
residues.  
The fact that any of the three 20S 
proteasome isoforms do not use even one 
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substrate cleavage site that is not used by 
the other two proteasome isoforms does 
not exclude that substrate cleavage sites 
can be preferentially used by one of the 
20S proteasome isoforms. We have 
verified this hypothesis through 
investigation of proteasome-mediated 
digestion kinetics of four substrates (i.e. 
gp100201-230, gp10035-57, MOG172-202, and 
MBP102-129). We have adopted a 
quantitative strategy in our MS analysis, 
using the Quantification with Minimal 
Effort (QME) methodology. QME 
estimates the absolute content of spliced 
and non-spliced peptide products based 
on their MS peak area, measured in the 
digestion probe (38). QME can also 
estimate the frequency of use of each 
substrate cleavage-site by proteasomes, 
i.e. in the substrate cleavage-site 
strength (SCS).  
According to our hypothesis, we have 
observed quantitative differences in the 
substrate cleavage-site predominantly 
used, between the three 20S proteasome 
isoforms (Fig. 5). There are no amino 
acids that are clearly preferred by one of 
the 20S proteasome isoforms rather than 
the others for peptide-bond hydrolysis, 
likely because the peptide sequence 
motifs (8-10 residues) surrounding the 
cleavage site influence the frequency of 
usage of that cleavage site. For instance, 
the gp100 L225 residue is seldom used by 
20S t-proteasome (Fig. 5A), although the 
MBP L112 (Fig. 5B) and the MOG L193 
residues are scarcely used by 20S i-
proteasome (Fig. 5C), which conversely 
prefers the gp100 L39 residue (Fig. 5D). 
For a more systematic comparison of the 
SCSs of the 20S proteasome isoforms we 
performed pairwise correlations between 
their SCSs. We have found significant 
pairwise correlations between SCSs of all 
three 20S proteasome isoforms, thereby 
indicating that their overall catalytic 
activity is comparable (Fig. 6). However, 
when we analyzed the SCS of specific 
substrates, differences emerge. These 
differences are due to specific substrate 
cleavage-sites, which are used by all 
three 20S proteasome isoforms although 
with divergent frequencies (e.g., gp100 
F215, L225, D226, L39, and A55). 
These quantitative differences in SCSs are 
also reflected in the generation of specific 
peptide products, including some that 
have already been shown to be epitopes 
recognized by CD8+ T cells. For instance, 
the epitope MBP111-119, which is a HLA-
A*02:01-binding epitope recognized by 
multiple sclerosis and healthy donor 
patients (39-43), is better generated by 
20S t-proteasome than 20S i-
proteasome. However, this phenomenon 
is epitope-specific since the generation of 
the epitope MBP107-115 (41) is not favored 
when carried out by human 20S t-
proteasome as compared to 20S i-




Diverging from what was shown for 
mouse 20S t-proteasome (30), human 
20S t-proteasome does not seem to 
possess a unique proteolytic activity in 
processing the self-antigen substrates 
included in this study and in our 
experimental conditions. We show here, 
however, that human 20S t- and i-
proteasome differ in their catalytic 
activity, peptide transport and transport 
regulation. The differences in the peptide 
transport are particularly relevant since 
the latter is often the rate-limiting step, 
at least in the degradation of short 
peptides, as also shown here for human 
20S t-proteasome. Differences in the 
peptide transport imply alterations of the 
overall 20S proteasome dynamics and 
long-range effects over the entire 
proteasome chamber due to the 
incorporation of the b5t subunit. As a 
consequence, the quantity of peptides 
produced by the b1i and b2i subunits 
(present in both t- and i-proteasome) can 
differ in case they are incorporated into 
either 2S t- or i-proteasome, since the 
peptide transport, and therefore the 
concentration and dynamics of peptides in 
these proteolytic pockets, could be 
altered too. 
These dissimilarities in catalytic activity, 
peptide transport and transport 
regulation can explain the variable 
preferences of human proteasome 
isoforms for specific substrate-cleavage 
sites. The fact that we have not observed 
cleavage sites only used by either 20S t- 
or i-proteasome could not be explained by 
the presence of standard catalytic 
subunits in our 20S t- and i-proteasome 
preparations. Indeed, if a substrate 
cleavage site is used only by 20S i-
proteasome, for instance, we shall not 
detect it in the 20S t-proteasome 
digestions and vice versa. Therefore, 
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although in our experimental set up we 
cannot exclude the existence of substrate 
cleavage sites exclusively used by human 
20S s-proteasome, we can exclude 
substrate cleavage sites exclusively used 
by either 20S i- or t-proteasome in the 
sequences analyzed in this study, as 
previously demonstrated already for 
human and mouse 20S i-proteasomes 
(22). This does not exclude the possibility 
that improving MS sensitivity could show 
a qualitative difference in the spliced and 
non-spliced products between 20S 
proteasome isoforms and this also does 
not provide direct information about 
differences between 20S proteasome 
isoforms coupled to 19S and other 
regulatory complexes. 
We have observed, however, strong 
variation from proteasome isoform to 
proteasome isoform in the quantity of 
peptides produced, including MHC-I-
binding epitopes, as shown here for the 
epitope MBP111-119. These quantitative 
differences in peptide generation can lead 
to a negligible presentation of epitopes at 
the cell surface as demonstrated in 
previous studies where mouse 20S s- and 
i-proteasomes have been compared 
(22,24,25). Our observations, therefore, 
are compatible with the hypothesis that 
cells expressing human 
thymoproteasome (both 20S 
proteasomes and 20S proteasomes 
coupled to regulatory complexes) could 
present on the cell surface some specific 
“private” epitopes, which could be directly 
involved in the positive selection of 
thymocytes (5). These “private” epitopes 
were not presented by cells expressing i-
proteasome - although they were 
produced in the intracellular space - 
because of the progressive reduction of 
the peptide amounts during the steps of 
the antigen presentation pathway (44). 
Different proteolytic dynamics between 
human i- and t-proteasomes could also 
result in significant variation in the 
turnover of specific antigens, and 
therefore in the antigenic landscape of 
cells expressing either t- or i-proteasome, 
which would further favor the “private 
epitopes” hypothesis. 
Our study also shows that 20S t-
proteasomes can generate spliced 
peptides, which are thought to represent 
a large portion of the MHC-I 
immunopeptidome; the peptides bound 
to MHC-I molecules (45-47). The 
generation of spliced epitopes by t- and i-
proteasomes in the thymus could strongly 
impinge upon our models of central 
tolerance and discrimination between self 
and non-self by our immune system (48). 
 
Material & Methods 
Cell lines  
To generate a cell line stably 
overexpressing the proteasome β5t 
subunit (protein: A5LHX3; gene: 
PSMB11), the thymic cDNA was 
transcribed from human thymic total RNA 
(Clontech Laboratories) by the 
Transcriptor First Strand cDNA Synthesis 
Kit (Roche Life Science) according to the 
manufacture’s instructions. For 
amplification of the human ß5t sequence 
(PSMB11) by PCR the following primers 
was used: fw 
5´gggatggctctgcaggatgtgtgc and rev 
5´ctcacaccgtctcagtccctgc. The PCR 
product was first inserted into 
pcDNA3.1(+) (Thermo Fisher Scientific) 
and then re-cloned into a pSG5 vector 
(Stratagene) via EcoR1/BamH1. T2 cells 
were cultured in RPMI supplemented with 
fetal bovine serum to a final concentration 
of 10% FBS, and 2 mM L- glutamine in 
5% CO2 atmosphere. Cells were 
transfected with pSG5/PSMB11, 
pSG5/PSMB9 (Lab stock) and pSVneo in 
equal amounts using the Amaxa Cell line 
Nucleofector® Kit C (Lonza). Stable 
transfected cells were selected with 1 
mg/ml G418 and the expression was 
controlled by PCR and western blotting. 
The positive cells were isolated and 
cultured again. The clone C5.5, which was 
transfected with ß5t (PSMB11) and ß1i 
(PSMB9) subunits, was selected for the 
study. 
To verify the endogenous expression of 
the ß5t subunit the following cell lines 
were grown in basal ISCOVE media 
supplemented with 10% FCS, 2mM 
glutamine and PenStrep in a 5% CO2 
atmosphere: i. T2 and C5.5 cell lines; ii. 
LCLs; iii. HeLa cell, 33.2 and 21.2 clones; 
the latter are stably transfected with HLA-
A*02:01 and ß1i+ß2i+ß5i subunits or 
ß1i+ß2i subunits respectively (49); iv. 
DU145 prostate carcinoma purchased 
from ATCC (ATCC® HTB-81™); v. RKO 
human colon carcinoma (ATCC CRL-
2577); vi. MeWo malignant melanoma 
(ATCC® HTB-65™); vii. human umbilical 
vein endothelial cells (HUVEC); viii. THP1 
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acute monocytic leukemia (ATCC® TIB-
202™); ix. Mel15 malignant melanoma 
(50); x. SaOs human bone osteosarcoma 
(ATCC HTB-85); A549 adenocarcinomic 
human alveolar basal epithelial cells 
(ATCC® CCL-185™). 
Western blots and b5t subunit 
identification and quantification 
Proteasome subunits have been revealed 
by western blot assays as previously 
described (22) using: anti-a4 (1:10000; 
in-house), anti-β1 (1:1000; Enzo Life 
Science), anti–β2 (1:1000; Enzo Life 
Science), anti-β5 (1:1000; Abcam), anti-
β1i (1:20000; in-house), anti–β2i 
(1:3000; Thermo Fisher), anti-β5i 
(1:1000; Santa Cruz Biotechnology), and 
anti-flag (1:1000; Sigma-Aldrich).  
For the identification of β5t subunit in 
different cell lines (Fig. 2B), bands have 
been excised from SDS-PAGE gel, washed 
with 200 mM ammonium bicarbonate in 
acetonitrile/water (50:50, v/v) and 50 
mM ammonium bicarbonate in 
acetonitrile/water (5:95, v/v) (digestion 
buffer), shrunk by dehydration in 
acetonitrile and dried. For reduction of 
cysteine residues 50 µl of 10 mM DTT in 
100 mM ammonium bicarbonate have 
been added and the samples have been 
incubated for 45 mins at 56°C. After 3 
times washing with water, 50 µl 55 mM 
iodoacetamide in 50 mM ammonium 
bicarbonate have been added. Incubation 
has been performed at room temperature 
in the dark for 20 mins. The gel bands 
have been washed with water and 
digestion buffer, and dried in acetonitrile 
after shrinking. 25 µl 0.1 g/l trypsin 
(Promega) in digestion buffer has been 
added and incubated at 37°C 
overnight. Tryptic-digested peptides have 
been extracted by one change of 25 µl 
0.5% TFA in acetonitrile/water (70:30, 
v/v), and 25 µl acetonitrile (10 min for 
each) at room temperature, combined 
and dried down. 
LC-MSMS analyses of peptides have been 
performed as following: the sample has 
been concentrated for 4 mins on a trap 
column (PepMap C18, 5 mm x 300 µm x 
5 µm, 100Ǻ, Thermofisher Scientific) with 
2:98 (v/v) acetonitrile/water containing 
0.1% (v/v) trifluoroacetic acid at a flow 
rate of 30 µl/min and then analyzed by 
nanoscale LC-MS/MS measurements 
using a Q Exactive Plus mass 
spectrometer coupled with an Ultimate 
3000 RSLCnano (ThermoFisher 
Scientific). The system comprised a 75 
µm i.d. × 250 mm nano LC column 
(Acclaim PepMap C18, 2 µm; 100 Å; 
ThermoFisher Scientific. The mobile 
phase (A) was 0.1% (v/v) formic acid 
(FA) in water, and (B) was 80:20 (v/v) 
acetonitrile/water containing 0.1% (v/v) 
FA. The elution has been carried out using 
a gradient 3-43% B in 80 min with a flow 
rate of 300 nl/min. Full MS spectra (m/z 
350–1,600) have been acquired at a 
resolution of 70,000 (FWHM) followed by 
a data-dependent MS/MS fragmentation 
of the top10 precursor ions (resolution 
17,500, 1+ charge state excluded, 
isolation window of 1.6 m/z, normalized 
collision energy of 27%, dissociation 
method HCD). The maximum ion injection 
time for MS scans has been set to 50 ms 
and for MS/MS scans to 120 ms. 
Background ions at m/z 391.2843 and 
445.1200 act as lock mass. Protein 
identifications has been performed with 
Mascot software version 2.6.1. (Matrix 
Science Ltd., London, UK). Data have 
been searched against SwissProt (July 
2017), taxonomy human (20,215 
sequences) and a contaminant database 
(247 sequences). The following 
parameters have been set: enzyme: 
trypsin/P with one missed cleavage, static 
modification: carbamidomethylation (C), 
variable modifications: protein N-
acetylation and oxidation (M), mass 
tolerances for MS and MSMS: 5 ppm and 
0.02 Da. Proteins have been accepted as 
identified if at least two unique peptides 
provided a Mascot MSMS score for 
identity (p<0.01). 
For relative protein quantification of β5 
and β5t subunits, two heavy AQUA 
peptides (Table S2) have been 
synthesized based on Fmoc solid phase 
chemistry, i.e. the heavy analogue 
peptide 226DAYSGGAVNLYHVR239 (with 
[M+H]+exp = 1528.80) of human b5 
subunit and the heavy analogue peptide 
216DAYSGGSVDLFHVR229 (with [M+H]+exp 
= 1529.79) of the human b5t subunit. 
During peptide synthesis, the heavy 
isotope-labeled amino acid Leucine-N-
Fmoc (U-13C6, N15) from Euriso-Top 
GmbH (Saarbrücken, Germany) has been 
incorporated. Estimation of exact peptide 
amount has been performed by amino 
acid analysis (Gennaxon Bioscience, Ulm 
Germany).  
β5/β5t subunit quantification of purified 
C5-5 20S proteasome reported in Fig. 2D 
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has been performed after LC separation 
of tryptic peptides on a MALDI-TOF/TOF 
mass spectrometer. In the assay (n = 2), 
5 µg proteasome have been reduced, 
alkylated and digested with trypsin as 
described elsewhere (51). Aliquots of the 
sample spiked with 500 fmol of each 
AQUA peptide have been analyzed by LC-
MS/MS on a 4700 Proteomics Analyzer 
(ABSCIEX, Framingham, MS) off-line 
coupled with a Dionex UltiMate 3000 
RSLC system and Probot fractionation 
device (Thermo Scientific, Idstein, 
Germany) as previously described (52). 
The calculation of the absolute amount of 
the tryptic peptides has been performed 
by comparison of the MS peak areas with 
those of the corresponding AQUA 
peptides. Based on the absolute amounts, 
the relative ratio b5:b5t has been 
determined as follows: b5t/(b5+b5t). 
RT-PCR and validation 
Total RNA has been isolated from human 
cell lines by High Pure RNA Isolation Kit 
(Roche) in presence of DNAse according 
manufactures protocol. The cDNA has 
been obtained from 1µg total RNA by 
Primer Script RT Reagent Kit (TaKaRa Bio 
Inc.). The RT-PCR has been performed 
with 1µl cDNAs for 25 cycles at an 
annealing temperature of 56°C. For the 
RT-PCR specific for the huPSMB11 gene, 
the following primers have been used: 
huPSMB11 Fw5´ 
gggatggctctgcaggatgtgtgc, and 
huPSMB11 Rev 5´ 
ctcacaccgtctcagtccctgc, thereby 
generating a transcript of 907 bp. To 
control the efficiency of RT-PCR, actin has 
been amplified from the cDNA by RT-PCR 
using the following actin specific primers: 
actin Fw 5´- ctcaccatggatgatatcg and 
actin Rev 5’ tcgtcatactcctgcttgctg. For the 
verification of the ß5t-subunit’s RT-PCR 
products the PCR products have been 
eluted from the agarose gel and inserted 
into pCR2.1 Topoâ (ThermoFisher) and 
sequenced by using the T7 primer by LCG 
Genomics GmbH (LGC group). The latter 
step has confirmed the specificity of the 
amplified sequence marked in Fig. 2A. 
Computational analysis of the 
proteasome dynamics 
20S proteasome degradation dynamics 
have been assessed using an integrative 
modeling approach with Bayesian model 
calibration to the in vitro degradation of 
the short fluorogenic peptides Suc-LLVY-
MCA, and Z-LLE-MCA. In vitro 
degradation kinetics (n=3-5) have been 
performed with different substrate 
concentration (0-480 µM) in 100 µl TEAD 
buffer (Tris 20 mM, EDTA 1 mM, NaN3 1 
mM, DTT 1 mM, pH 7.2) at 37°C as 
previously described (22). For the 
analysis we have used the computational 
model of 20S proteasome activity 
previously published (11). In an essence, 
by applying approximate Bayesian 
computation to fit the model to the 
experimental data, we have obtained 
posterior parameter distributions for each 
proteasome isoform. The comparison of 
the marginal posterior parameter 
distributions has allowed us to detect 
differences in the kinetics parameters 
between the different isoforms. For the 
Bayesian inference we have used the 
package ABC-SysBio (12) implemented in 
Python with GPU support (53). The prior 
distributions for all parameters was 
uniform, as described in (11). 
Furthermore, all other algorithm 
parameters have been kept as in Liepe et 
al. (11). The posterior analysis has been 
carried out in R (54). Computation of 
rate-limiting steps has been performed as 
described in Liepe et al. (11). 
20S proteasome purification  
20S proteasomes have been purified from 
T2, C5.5 and LCL, as previously described 
(55). Proteasome concentration has been 
measured by Bradford staining and 
verified by Coomassie staining in a SDS-
Page gel, as show elsewhere (56). The 
purity of the standardized proteasome 
preparations has been previously shown 
(22). LCL and C5.5 cell lines mainly 
express human i-proteasome (22,57) or 
t-proteasomes, respectively (Fig. 2). LCL 
proteasome has been often used as an 
example of i-proteasome in several 
previous studies (22,38,39,50,57-61). T2 
cell line expresses only s-proteasome 
(Fig. 2). The three proteasomes have 
been purified in parallel to minimize 
artifacts due to the purification or storage 
conditions. 
Peptides and in vitro digestion of 
synthetic polypeptides 
The sequence enumeration for the 
polypeptide substrates is reported in 
Table S1. All peptides have been 
synthesized using Fmoc solid phase 
chemistry. Synthetic polypeptides (20-40 
µM) have been digested by 1-3 µg 20S 
proteasomes in 100 µl TEAD buffer over 
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time at 37°C, as previously described 
(22).  
Quantitative analysis of peptide 
products by QME and MS 
Liquid-chromatography MS analyses of 
polypeptide digestion products have been 
performed as previously described (52) 
with the ESI-ion trap instrument DECA XP 
MAX (ThermoFisher Scientific, USA). 
Database searching has been performed 
using the SpliceMet’s ProteaJ (52). 
Quantification of peptides produced in the 
experiments have been carried out by 
applying QME method to the LC-MS 
analyses. QME estimates the absolute 
content of spliced and non-spliced peptide 
products based on their MS peak area 
measured in the digestion probe. QME is 
an optimization tool that makes use of the 
law of mass conservation and mass 
spectrometry instrument features. The 
QME algorithm parameters were 
empirically computed in our previous 
study (38) and have been here applied. 
By applying QME we have also calculated 
the SCS, which describes the relative 
frequencies of proteasome cleavage after 
any given residue of the synthetic 
polypeptide substrate. SCS values shown 
in this study are the average of SCS 
measured in kinetics assays. 
Statistical analysis 
The SCS correlation has been done using 
Pearson’s correlation coefficient. 
Significance tests have been performed 
testing for association between paired 
samples based on Pearson’s correlation 
coefficient. All data analysis have been 
implemented in R (54). Sample size and 
number of replicates are disclosed in the 
figure and table captions. 
Data and Software Availability 




Datasets linked to the computational 
model of proteasome dynamics and 




The statistical background behind the 
model inference presented in this study is 
described in (12,13) and its 
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kp peptide-bond hydrolysis rate at active site(s) 
KaS, KaP dissociation constant of substrate (S) and product (P) to active site(s) 
na Hill coefficient for binding to active site(s) 
 
KiS and KiP dissociation constant of substrate (S) and product (P) to inhibitor site(s) 
ni Hill coefficient for binding to inhibitor site(s) 
a factor, by which KaS, KaP, KiS and KiP are multiplied 
b factor, by which kp is multiplied upon binding to inhibitory site(s) 
Transport 
kon association rate to the gate 
koff dissociation rate to from gate 
vin peptide influx rate 
t peptide translocation rate inside the chamber 
vout peptide efflux rate 
C capacity (maximum number of molecules inside the chamber) 
transport regulation 
Ron binding rate to the enhancing regulator site(s) 
Roff unbinding rate to the enhancing regulator site(s) 
Xenh strength of enhancing regulator site(s) 
Ion binding rate to the inhibiting regulator site(s) outside the chamber 
Ioff unbinding rate to the inhibiting regulator site(s) outside the chamber 
H coefficient for binding to inhibiting regulator site(s) outside the chamber 
Yin strength of inhibiting regulator site(s) 
 
Table 1. List of mathematical model parameters. The table and the meaning of the 
parameters have been previously published by Liepe et al. (11) and they correspond to 





Figure 1. Overview of the computational modeling approach describing the 
proteasome proteolytic dynamics. In (A) the schematic of the compartmentalized 
proteasome model proposed by Liepe and colleagues (11) is shown. The model describes 
all relevant steps involved in substrate degradation. These include (i) peptide transport 
steps (peptide binding close to the outer site of the gate, peptide influx into the chamber, 
peptide translocation inside the chamber and peptide efflux out of the chamber), (ii) 
substrate hydrolysis steps (peptide binding to the active site and subsequent hydrolysis, 
and peptide binding to the non-catalytic inhibitor site) and (iii) transport regulation 
(peptide binding to the non-catalytic enhancer site, peptide binding to the non-catalytic 
inhibitor site and resulting effects on the conformation of the proteasome gate). The grey 
chamber represents a simplification of the 20S proteasome catalytic chamber with 
openings to the outside. The substrate and product peptides (purple) can enter the 20S 
proteasome chamber upon binding to the outer face of the gate, interact with the 
regulatory and catalytic sites inside the chamber, and can leave the proteasome chamber 
upon translocation to the proximity of the inner face of the gate. Grey arrows indicate the 
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transport of substrate and product peptides. The orange arrow denotes the hydrolysis 
reaction where a substrate peptide is transformed into product peptide, thereby releasing 
the fluorophore. Enhancing regulatory sites inside the chamber are shown in blue with the 
dashed arrows indicating their effect (transport enhancing gate conformation). The 
inhibiting regulatory site outside the chamber is shown in light blue with the dashed arrow 
indicating its effect (transport inhibiting gate conformation). The catalytic site consists of 
an active site (light orange) and an inactive modifier site (dark orange). For details of the 
model equations, model setup and model parameters, please refer to (11). In (B) the 
schematic of Bayesian inference is sketched. Computational models describing biological 
systems are often parameterized. These parameters can be abstract, or as it is the case 
here, they can be kinetics parameters with a direct physical translation. In order to learn 
anything from the model, it is necessary to calibrate the model against experimental data. 
This can be done in many fashions, however, in the last decade Bayesian inference 
techniques proved to be powerful model calibration tools. One of the advantages of 
Bayesian inference is that it estimates not only the model parameters, but also their 
uncertainty. In general, experimental data are collected and a computational model is 
formulated. Both are then used as input for the Bayesian inference algorithm (here 
approximate Bayesian computation). The basic concept of the algorithm is to test all sort 
of combinations of parameters (through a defined sampling scheme) and simulate the 
model with those parameter combinations. If the model simulations correspond well to the 
experimental data, the corresponding parameter combination is accepted; otherwise the 
parameter combination is discarded. This is done repeatedly until a certain number of 
accepted parameter combinations is reached, which then construct the so-called posterior 
parameter distribution. This posterior distribution contains all information about the 
separate model parameters as well as their dependencies among each other. The outputs 
of Bayesian inference are therefore the model fits of the experimental data and the 
posterior parameter distributions. Calibrating the same model to experimental data 
generated under different conditions (here different proteasome isoforms) allows us to 
compare the obtained posterior parameter distributions and detect which model 





Figure 2. Catalytic b subunit expression in different human cell lines. A) RT-PCR 
products specific for PSMB11 (b5t subunit) or actin (as control) obtained from different 
immortalized or tumor-derived human cell lines. The specific band of the PSMB11 is marked 
with a red arrow. Specificity has been confirmed by cloning and sequencing the cDNA 
extracted from the band.  B) MS identification of the b5t subunit in the cell lysate of the 
same cell lines showed in (shown in A). Cell lysates have been separated on a SDS gel and 
stained with Coomassie (left panel; only some representative cell samples are shown), the 
proteins framed in the picture have been cut, digested by trypsin and the b5t subunit-
specific peptides have been detected by MS. Only for the C5.5 cell line we have identified 
the b5t subunit products (marked with bold letters: 19 specific peptides depicted below the 
gel) with significant MS/MS spectra (the spectrum of one of them is depicted in the right 
panel). C) Western blot assays for proteasome catalytic subunits, which have been carried 
out after separation of 0.5 µg purified 20S proteasomes in SDS-Page, are shown. D) 
Relative quantification of the subunit b5 (PSB5_human) and b5t (PSB11_human) of purified 
20S proteasome after absolute quantification with AQUA peptides. Shown are 
representative MALDI-MS/MS mass spectrometry spectra of the tryptic peptide 
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226DAYSGGAVNLYHVR239 with [M+H]+exp = 1521.78 and its heavy analogue with [M+H]+exp 
= 1528.80 of b5 subunit at spot 42 and 216DAYSGGSVDLFHVR229 with [M+H]+exp = 1522.77 
and its heavy analogue with [M+H]+exp = 1529.79 of b5t subunit at spot 69. The calculation 
of the absolute amount of the tryptic peptides is performed by comparison of the MS peak 





Figure 3. Computational model parameters and rate-limiting steps of proteasome 
isoform dynamics. A-B) Marginal posterior parameter distributions obtained by 
calibrating the proteasome kinetics model against experimental data (n=3-5) derived from 
the degradation of the substrate Suc-LLVY-MCA by 20S s-, i- and t-proteasomes. 
Parameters are grouped into active site-related parameters (A) and transport- and 
transport regulation-related parameters (B). Briefly, KaS, KaP are the dissociation constant 
of substrate (S) and product (P) to active site(s); kp is the peptide-bond hydrolysis rate at 
active site(s); b is factor by which kp is multiplied upon binding to inhibitory site(s); na and 
ni are the Hill coefficients for binding to the active site(s) and the inhibitor site(s); KiS and 
KiP are the dissociation constants of substrate (S) and product (P) to inhibitor site(s); vin 
and vout are the peptide influx and efflux rates and vin/vout is their ratio; Koff/Kon is the ratio 
between the dissociation and the association rates to the gate; Roff/Ron is the ratio between 
the unbinding and binding rate to the enhancing regulator site(s). The meaning of all 
parameters is depicted in Fig. 1 and Table 1. C-D) Analysis of rate-limiting steps in 20S 
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i- and t-proteasomes. Depicted is the fold change of product formation (y axis) upon 
increase (by a factor of; x axis) of a specific reaction step for the degradation of Suc-LLVY-
MCA (C) and Z-LLE-MCA (D), as simulated by our computational model of the 20S 
proteasome dynamics. The initial substrate concentration for this analysis is 160 µM and 
the fold change is determined after 60 min reaction relative to the experimentally 
measured proteasome kinetics (factor = 1). The mean of 1000 in silico predictions (colored 
lines) is plotted over time for the degradation of the substrates with the same initial 
substrate concentrations as in the experiments. The rate-limiting steps are those which 





Figure 4. Simulation of the substrate and product dynamics inside the chambers 
of the human s-, i- and t-proteasomes. The mean of 1000 in silico predictions (colored 
lines) is plotted over time for the degradation of the substrates Z-LLE-MCA (A) or Suc-
LLVY-MCA (B) with the same initial substrate concentrations as used in the independent 
experiments (n=3-5; see Material & Methods). The simulation has been performed for 20S 
i- and t-proteasomes. The number of peptide molecules (product and substrate) and the 
relative amount of products vs total amount of peptides inside the chambers over time has 
been computed by the computational model and it is based on the estimated posterior 





Figure 5. Different proteasome isoforms preferentially use different substrate 
cleavage-sites. A-D) The relative frequency of the substrate cleavage-site usage (i.e. the 
SCS of the synthetic substrates gp100201-230 (A), MBP102-129 (B), MOG172-202 (C), and 
gp10035-53 (D) by 20S s-, i- and t-proteasome are shown as mean of 2-4 independent 
experiments (bars are the SD) measured 2-3 times. Quantitative analyses are done by 





Figure 6. Proteasome isoforms overall share a common substrate cleavage-sites  
usage, with specific differences. The correlation between the SCSs of the synthetic 
substrates gp100201-230 (dots in pink), gp10035-53 (dots in blue), MBP102-129 (dots in green), 
and MOG172-202 (dots in black) generated in in vitro digestion kinetics by human 20S s-, i- 
or t-proteasomes. The SCSs are compared in proteasomes’ pairwise. The computed 
Pearson’s correlation coefficients and the tests for significance of these correlations are 
reported. Non-significant correlations are marked in bold, which depict SCSs that differ 
between the pair of compared 20S proteasome types. The substrate cleavage-sites which 





Figure 7. Proteasome isoforms generate MBP epitopes with different kinetics. The 
degradation kinetics of the synthetic substrates MBP102-129 by 20S s-, i- and t-proteasomes, 
and the generation kinetics of the epitopes MBP111-119 and MBP107-115, is shown. The mean 
of 2-4 independent experiments (bars are the SD) measured in duplicate is shown. 
Quantitative analyses are done by applying QME to the mass spectrometry measurements. 
 
 
